Novel CD123 polyaptamer hydrogel edited by Cas9/sgRNA for AML-targeted therapy.

Drug Delivery
Haibin WuHui Li

Abstract

CD123 targeting molecules have been widely applied in acute myelocytic leukemia (AML) therapeutics. Although antibodies have been more widely used as targeting molecules, aptamer have unique advantages for CD123 targeting therapy. In this study, we constructed an aptamer hydrogel termed as SSFH which could be precisely cut by Cas9/sgRNA for programmed SS30 release. To construct hydrogel, rolling-circle amplification (RCA) was used to generate hydrogel containing CD123 aptamer SS30 and sgRNA-targeting sequence. After incubation with Cas9/sgRNA, SSFH could lose its gel property and liberated the SS30 aptamer sequence, and released SS30 has been confirmed by gel electrophoresis. In addition, SS30 released from SSFH could inhibit cell proliferation and induce cell apoptosis in vitro. Moreover, SSFH could prolong survival rate and inhibit tumor growth via JAK2/STAT5 signaling pathway in vivo. Additionally, molecular imaging revealed SSFH co-injected with Cas9/sgRNA remained at the injection site longer than free aptamer. Furthermore, once the levels of cytokines were increasing, the complementary sequences of aptamers injection could neutralize SS30 and relieve side effect immediately. This study suggested that CD123 aptamer hydroge...Continue Reading

References

Feb 25, 2015·Biotechnology Advances·Mariia DarmostukTomas Ruml
Jun 10, 2015·Biomaterials·Mi-Gyeong KimYu-Kyoung Oh
Jul 3, 2015·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Hongguang Sun, Youli Zu
Oct 1, 2014·Molecular & Cellular Oncology·Timothy R HercusAngel F Lopez
May 31, 2017·Seminars in Immunopathology·Benjamin G ChoustermanGeorg F Weber
Dec 29, 2017·Langmuir : the ACS Journal of Surfaces and Colloids·Peter A MirauRajesh Naik
Jul 26, 2018·Methods in Molecular Biology·Ze Hong LeeToshiro Ito
Aug 21, 2018·Advanced Drug Delivery Reviews·Guizhi Zhu, Xiaoyuan Chen
Sep 9, 2018·Biochimie·Payam BayatMohammad Ramezani
Jan 30, 2019·Expert Opinion on Drug Delivery·Lin-Yan WanJiang-Feng Wu
Jun 28, 2019·Cardiovascular & Hematological Disorders Drug Targets·Mingyue ShiMingyi Chen
Aug 23, 2019·The Journal of Clinical Investigation·Katsuhiro TogamiAndrew A Lane
Sep 29, 2019·Langmuir : the ACS Journal of Surfaces and Colloids·Yuqing LiJuewen Liu
Nov 30, 2019·Best Practice & Research. Clinical Haematology·Saar I Gill
Jan 29, 2020·JCI Insight·Yao TongBill B Chen
Apr 22, 2020·ACS Applied Materials & Interfaces·Jiao ZhangChuan Zhang
Apr 28, 2020·Hematology/oncology Clinics of North America·Mayumi Sugita, Monica L Guzman
Jun 13, 2020·Journal of Inflammation·Gagandeep KaurIrfan Rahman
Aug 31, 2020·Clinical Lymphoma, Myeloma & Leukemia·Andrew A Lane
Dec 7, 2020·Best Practice & Research. Clinical Haematology·Michael J Slade, Geoffrey L Uy
Dec 19, 2020·Signal Transduction and Targeted Therapy·Jenna L CarterYubin Ge
Feb 25, 2021·Chemical Communications : Chem Comm·Yudai TabuchiMasumi Taki
Mar 25, 2021·Journal of Hematology & Oncology·Hongtao Liu
Mar 25, 2021·The Journal of Experimental Medicine·Lucille StuaniJean-Emmanuel Sarry
Mar 26, 2021·Best Practice & Research. Clinical Haematology·Jacob M Rowe

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis